The Foundation Fighting Blindness is the world’s leading private funding source for research to prevent, treat, and cure retinal degenerative diseases. Many of the trials listed below were made possible by Foundation support.
Genetic Technologies
GENE THERAPIES (GENE TARGET)
| Disease/Condition | Company | Clinical Trial Phase |
|---|---|---|
| AMD-dry, GA (RORA) | Ocugen | Phase 3 |
| AMD-dry, GA (CFH) | Perceive Bio | Phase 1/2 |
| AMD-dry, GA (CR1) | Complement Tx | Phase 1/2 |
| Bardet-Biedl Syndrome (BBS1) |
Axovia |
|
| Batten disease (CLN2) |
Tern Therapeutics |
|
| Batten disease (CLN5) | Neurogene | Phase 1/2 |
| BCD (CYP4V2) | Shanghai Vitalgen | Phase 3 |
| Best disease (BEST1) | Opus Genetics | Phase 1/2 |
| LCA (GUCY2D) | Atsena | Phase 1/2 |
| LCA (LCA5) | Opus Genetics | Phase 1/2/3 |
| LCA, RP (RDH12) | Peking Union Medical College Hosp | Phase 1 |
| RLBP1 Retinal Dystrophy (RLBP1) | Peking Union Medical College Hosp | Phase 1 |
| RP (CNGA1) | VeonGen | Phase 1 |
| RP (NR2E3, gene agnostic) | Ocugen | Phase 3 |
| RP (RdCVF, gene agnostic) | SparingVision | Phase 1/2 |
| Stargardt disease (RORA) | Ocugen | Phase 2/3 |
| Stargardt disease (ABCA4) | Splice Bio | Phase 1/2 |
| Stargardt disease (ABCA4) | VeonGen | Phase 1/2 |
| Stargardt disease (ABCA4) | AAVantgarde | Phase 1/2 |
| Usher syndrome (MYO7A) | AAVantgarde | Phase 1/2 |
| X-linked Retinoschisis (RS1) | Atsena | Phase 1/2/3 |
| X-linked RP (RPGR) | Beacon | Phase 2/3 |
| X-linked RP (RPGR) | MeiraGTx | Phase 3 |
RNA THERAPIES (MECHANISM)
| Disease/Condition | Company | Clinical Trial Phase |
|---|---|---|
| AMD-dry, GA (siRNA targeting CFB) | ADARx | Phase 2 |
| AMD-dry, GA (RNAi for undisclosed target) | Genentech | Phase 2 |
| LCA10 (AON targeting CEP290 IVS26) | Sepul Bio | Phase 3 |
| RP11 (AON targeting CNOT3) | PYC | Phase 1/2 |
| RP, Usher (AON targeting USH2A exon 13) | Sepul Bio | Phase 2 |
| Stargardt disease (ABCA4 RNA editing) | Ascidian | Phase 1/2 |
| Stargardt disease (RNAi targeting RBP4) | City Therapeutics | Phase 1 |
Novel Medical Therapies
SMALL MOLECULES, PROTEINS (INVESTIGATIONAL PRODUCT)
| Disease/Condition | Company | Clinical Trial Phase |
|---|---|---|
| AMD-dry, GA (Gildeuretinol) | Alkeus | Phase 2/3 |
| AMD-dry, GA (ANX007) | Annexon | Phase 3 |
| AMD-dry, GA (Tinlarebant) | Belite Bio | Phase 3 |
| AMD-dry, GA (BRX001) | Biojiva | Phase 1/2 |
| AMD-dry, GA (BI 771716) | Boehringer Ingelheim | Phase 2 |
| AMD-dry, GA (BI 1584862) | Boehringer Ingelheim | Phase 2 |
| AMD-dry, GA (ONL1204) | ONL Therapeutics | Phase 2 |
| AMD-dry, GA (Elamipretide) | Stealth Bio | Phase 3 |
| AMD-dry, GA (Pozelimab, Cemdisiran) | Regeneron | Phase 3 |
| AMD-dry, GA (FWY003) | Novartis | Phase 2 |
| RP, CHM (KIO-301) | Kiora | Phase 2 |
| RP (Disulfiram) | University of Washington | Phase 1/2 |
| RP (NAC) | Johns Hopkins University | Phase 3 |
| RP-RHO (OCT-980) | Octant Bio | Phase 1/2 |
| RP (Pitavastatin nanoparticles) | Kyushu University | Phase 1 |
| Stargardt disease (Gildeuretinol) | Alkeus | Phase 2 |
| Stargardt disease (Tinlarebant) | Belite Bio | Phase 2/3 |
| Stargardt disease (Metformin) | NEI | Phase 1/2 |
| Usher syndrome (NACA) | Nacuity | Phase 3 |
| Usher syndrome 3 (BF844) | USH III Initiative | Phase 1 |
Restorative Therapies
CELL-BASED THERAPIES (CELL TYPE)
| Disease/Condition | Company | Clinical Trial Phase |
|---|---|---|
| AMD-dry, GA (RPE) | Astellas | Phase 1 |
| AMD-dry, GA (RPE) | Eyestem | Phase 1/2 |
| AMD-dry, GA (RPE) | Lineage/Genentech | Phase 2 |
| AMD-dry, GA (RPE) | Luxa Bio | Phase 1/2 |
| AMD-dry, GA (RPE) | NEI | Phase 1/2 |
| AMD-dry, GA (RPE) | Regenerative Patch | Phase 2 |
| AMD-dry, GA, Stargardt (RPE) | Cellio | Phase 1 |
| RP, Usher, CRD (retinal precursors) | BlueRock | Phase 1/2 |
| RP, Usher (retinal progenitors) | jCyte | Phase 2b |
| RP (iPSC retinal sheets) | Sumitomo Pharma | Phase 1/2 |
| RP (RPE) | Centre D'Etude Des Cellules Souches | Phase 1/2 |
OPTOGENTIC THERAPIES (CELL TARGET)
| Disease/Condition | Company | Clinical Trial Phase |
|---|---|---|
| AMD-dry, GA (RGCs) | Bionic Sight | Phase 1/2 |
| RP (RGCs) | Zhongmou Therapeutics | Phase 1 |
| RP (Cones) | SparingVision | Phase 1/2 |
| RP (BCs) |
Restore Vision |
Phase 1/2 |
| RP (RGCs) | Bionic Sight | Phase 1/2 |
| RP (RGCs) | GenSight | Phase 1/2 |
| RP (BCs) | Nanoscope | Phase 2 |
| RP, CHM (RGCs) | Ray Therapeutics | Phase 1 |
| Stargardt disease (BCs) | Nanoscope | Phase 2 |
| Stargardt disease (BCs) | Ray Therapeutics | Phase 1/2 |
RETINAL PROSTHETICS (DEVICE LOCATION)
| Disease/Condition | Company | Clinical Trial Phase |
|---|---|---|
| IRDs, Stargardt, RP (PRIMA, Subretinal) | Science Corporation | Pilot Phase |
Approved Therapies
| Disease/Condition | Company | Clinical Trial Phase |
|---|---|---|
| AMD-dry, GA (SYFOVRE, C3 inhibitor) | Apellis | Approved |
| AMD-dry, GA (IZERVAY, C5 inhibitor) | Astellas | Approved |
| LCA (LUXTURNA, RPE65) | Spark/Roche | Approved |
| AMD-dry, GA (PRIMA, retinal prosthetic) | Science Corp | Approved in European Union |
Note: This is not a complete list. Some trials listed may have been paused and/or the sponsors are seeking partners to continue their trials. To learn more about additional clinical trials underway for inherited retinal diseases and geographic atrophy, visit www.ClinicalTrials.gov. The site lists detailed information about many relevant trials, including eligibility criteria and sponsor contact information.